No Detail Found!

Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination

Author(s)
Humaira Majeed Khan Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University (LCWU),Lahore,Pakistan
Huma Nawaz Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University (LCWU),Lahore,Pakistan
Huma Aerooj Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University (LCWU),Lahore,Pakistan
Ali Sharif Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University (LCWU),Lahore,Pakistan
Abstract
Type 2 Diabetes Mellitus (T2DM) patients are at high risk of Coronary Heart Disease (CHD) and need a global therapeutic intervention. A fixed-dose combination prescription medication containing anti-diabetic drug (Sitagliptin) and lipid lowering (Simvastatin) has recently been approved. Present study was designed to explore the potential synergistic toxic effects of sitagliptin and simvastatin at cellular level. MTT assay revealed the potential synergistic cytotoxic effect whereas Comet assay spotlighted the genotoxicity. MTT assay conducted on Vero cell lines revealed no significant change in proliferative activity upon treatment with simvastatin but cell survival percentage (CSP) decreased upon treatment with sitagliptin (51% at 1000µg/mL). However, combination of both drugs exhibited a better survival percentage except highest dose combination (1000:500µg/mL) which augmented antiproliferative effects rendering CSP 71.6%. The genotoxic assay spotted that Simvastatin produced less damage to DNA with the threshold of 500µg/ml whereas Sitagliptin significantly damage above the 250µg/mL, However, combination of drugs produced lesser damage than Sitagliptin alone. The findings concluded a non-genotoxic combination of sitagliptin and simvastatin which possess a least cytotoxic potential suggesting the safe use of the combination both in T2DM and CHD.
Publication Details
Page(s) 1939-1944
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP5, Year: 2021

Request the full text from PASTIC

Keywords
Simvastatin, Comet assay, Sitagliptin, MTT assay
References
Ahmad OS,Morris JA,Mujammami M,Forgetta V,Leong A,Li R,Turgeon M,Greenwood CM,Thanassoulis G,Meigs JB .2015 .A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat. Commun, 6(1) : 1-11.
Auwal F,Dahiru MN,Abdu-Aguye SN,Pract SN .2019 .Availability and rationality of fixed dose combinations available in Kaduna, Nigeria. , 17(2) : 1-5.
Azqueta A,Collins AR .2013 .The essential comet assay: A comprehensive guide to measuring DNA damage and repair. Arch, 87(6) : 949-968.
Błaszczyk B,Miziak B,Czuczwar P,WierzchowskaCioch E,Pluta R,Czuczwar SJ .2018 .A viewpoint on rational and irrational fixed-drug combinations. Expert Rev. Clin. Pharmacol, 11(8) : 761-71.
Colhoun HM,Betteridge DJ,Durrington PN,Hitman GA,Neil Haw,Livingstone SJ,Thomason MJ,Mackness MI,Charlton-Menys V,Fuller JH .2004 .Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): Multicentre randomised placebo-controlled trial. The Lancet., 364(9435) : 685-696.
Damrot J,Nübel T,Epe B,Roos W,Kaina B,Fritz G .2006 .Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol., 149(8) : 988-997.
De Sousa JA,Pereira P,Da Costa Allgayer M,Marroni NP .2017 .Evaluation of DNA damage in Wistar rat tissues with hyperlipidemia induced by tyloxapol. Exp. Mol. Pathol, 103(1) : 51-55.
Donmez-Altuntas H,Bayram F,Coskun-Demirkalp AN,Baspınar O,Kocer D,Toth PP D .2019 .Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients. Exp Biol Med, 244(13) : 1089-1095.
Rakhmanina N Dubrocq G .2018 .The pharmacokinetics, pharmacodynamics and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection. Expert Opin Drug Met, 14(8) : 773-9.
Franzoni F,Quiñones-Galvan A,Regoli F,Ferrannini E,Galetta F E .2003 .A comparative study of the in vitro antioxidant activity of statins. Int. J. Cardiol., 90(2-3) : 317-321.
Girona J,La Ville AE,Solà R,Plana N,Masana LS .1999 .Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Card., 83(6) : 846-851.
Godman B,McCabe H,D Leong T,Mueller D,Martin AP,Hoxha I .2020 .Fixed dose drug combinations are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries. Expert Rev Pharm Out, 20(1) : 1-26.
Gul OO,Cinkilic N,Gul CB,Cander S,Vatan O,Ersoy C,Yılmaz D,Tuncel E .2013 .Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study. Mutat Res-Gen Tox En., 757(1) : 31-35.
Gupta R,Malhotra A,Malhotra P .2018 .Assessment of rational use of fixed dose combinations in hypertension in a tertiary care teaching hospital in north India. Int. J. Adv. Med, 5(5) : 1263-1267.
Inzucchi SE,Bergenstal RM,Buse JB,Diamant M,Ferrannini E,Nauck M,Peters AL,Tsapas A,Wender R,Matthews DR .2015 .Management of hyperglycemia in type 2 diabetes, 2015: A patientcentered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. , 38(1) : 140-149.
Menditto E,Orlando V,De Rosa G,Minghetti P,Musazzi UM,Cahir C .2020 .Patient centric pharmaceutical drug product design. The impact on medication adherence. , 12(1) : 44.
Pedersen TR,Tobert JA .2004 .Simvastatin: A review. Expert Opin Pharmaco. , 5(12) : 2583-2596.
Ramadan WH,Kabbara WK .2015 .Sitagliptin/Simvastatin: A first combination tablet to treat type 2 diabetes and hypercholesterolemia a review of its characteristics. Vasc Health Risk Manag., 11 : 125.
Ramesh B,Manjula N,Bijargi S,Sarma V,Devi PS .2015 .Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESIMS/MS. , 5(3) : 161-168.
Seidl K,Zinkernagel AS K .2013 .The MTT assay is a rapid and reliable quantitative method to assess Staphylococcus aureus induced endothelial cell damage. J. Microbiol. Methods., 92(3) : 307-309.
Sharif A,Akhtar MF,Akhtar B,Saleem A,Manan M,Shabbir M,Ashraf M,Peerzada S,Ahmed S,Raza M .2017 .Genotoxic and cytotoxic potential of whole plant extracts of Kalanchoe laciniata by Ames and MTT assay. , 16(1) : 593.
Sharif A,Ashraf M,Anjum AA,Javeed A,Altaf I,Akhtar MF,Abbas M,Akhtar B,Saleem A .2016 .Pharmaceutical wastewater being composite mixture of environmental pollutants may be associated with mutagenicity and genotoxicity. Environ. Sci. Pollut, 23(3) : 2813-2820.
Singh NP,Mccoy MT,Tice RR,Schneider EL .1988 .A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res, 175(1) : 184-191.
Ylvester PW .2011 .Drug Design and Discovery. Methods in Molecular Biology (Methods and Protocols), 175(1) : 184-191.
Yuzbasioglu D,Enguzel-Alperen C,Unal F C .2018 .Investigation of in vitro genotoxic effects of an antidiabetic drug sitagliptin. Food Chem, 112(1) : 235-241.
Zonoozi S,Barnard M,Prescott E,Jones R,Shah FT,Tzoulis P .2017 .Effectiveness and safety of sitagliptin in patients with beta-thalassaemia major and diabetes mellitus: A case series. Mediterr. J. Hematol. Infect Dis, 9(1) : e2017004.
0

Citations

0

Downloads

14

Views